Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Kathryn Gold

    TitleAssociate Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0658
    CA La Jolla 92093
    vCardDownload vCard

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Feb 21; JCO2016703223. PMID: 28221867.
        View in: PubMed
      2. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold K, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Nov 7. PMID: 27836716.
        View in: PubMed
      3. Owens RL, Gold K, Gozal D, Peppard PE, Jun JC, Lippman SM, Malhotra A. Sleep and Breathing … and Cancer? Cancer Prev Res (Phila). 2016 Nov; 9(11):821-827. PMID: 27604751.
        View in: PubMed
      4. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016 Jul 25. PMID: 27458307.
        View in: PubMed
      5. Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold K, Shin DH, Creighton CJ, Gibbons DL. The microRNA-200/Zeb1 axis regulates ECM-dependent ß1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci Rep. 2016; 6:18652. PMID: 26728244.
        View in: PubMed
      6. Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold K, Frank SJ, Skinner H, Rosenthal DI, Garden AS. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck. 2016 Apr; 38 Suppl 1:E1554-61. PMID: 26595157.
        View in: PubMed
      7. Xing Y, Zhang J, Lin H, Gold K, Sturgis EM, Garden AS, Lee JJ, William WN. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer. 2016 Feb 15; 122(4):534-45. PMID: 26554754.
        View in: PubMed
      8. Shoultz-Henley S, Garden AS, Mohamed AS, Sheu T, Kroll MH, Rosenthal DI, Gunn GB, Hayes AJ, French C, Eichelberger H, Kalpathy-Cramer J, Smith BD, Phan J, Ayoub Z, Lai SY, Pham B, Kies M, Gold K, Sturgis E, Fuller CD. Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. Int J Cancer. 2016 Mar 1; 138(5):1290-7. PMID: 26414107.
        View in: PubMed
      9. Carrizosa DR, Gold K. New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2015 Oct; 4(5):553-9. PMID: 26629424.
        View in: PubMed
      10. Gold K, Erasmus JJ. FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Aug; 10(8):1131-2. PMID: 26200266.
        View in: PubMed
      11. Takiar V, Ma D, Garden AS, Li J, Rosenthal DI, Beadle BM, Frank SJ, Fuller CD, Gunn GB, Morrison WH, Hutcheson K, El-Naggar AK, Gold K, Kupferman ME, Phan J. Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. Head Neck. 2016 Apr; 38 Suppl 1:E925-33. PMID: 25994561.
        View in: PubMed
      12. Liu X, Gold K, Dmitrovsky E. The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target. Mol Cancer Ther. 2015 Jun; 14(6):1273-5. PMID: 25995438.
        View in: PubMed
      13. Zhang J, Gold K, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN. Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry. J Thorac Oncol. 2015 Apr; 10(4):682-90. PMID: 25590605.
        View in: PubMed
      14. Gold K. ROS1--targeting the one percent in lung cancer. N Engl J Med. 2014 Nov 20; 371(21):2030-1. PMID: 25409376.
        View in: PubMed
      15. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold K, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9. PMID: 25301631.
        View in: PubMed
      16. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold K, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9). PMID: 25214559; PMCID: PMC4200057 [Available on 09/01/15].
      17. Gold K, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct; 19(10):1040-1. PMID: 25170013; PMCID: PMC4201000.
      18. Gold K, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 1; 20(7):1946-54. PMID: 24366692; NIHMSID: NIHMS552097 [Available on 04/01/15].
        View in: PubMed
      19. Ferrarotto R, Gold K. Afatinib in the treatment of head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2014 Jan; 23(1):135-43. PMID: 24266694.
        View in: PubMed
      20. Hutcheson KA, Bhayani MK, Beadle BM, Gold K, Shinn EH, Lai SY, Lewin J. Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it. JAMA Otolaryngol Head Neck Surg. 2013 Nov; 139(11):1127-34. PMID: 24051544; NIHMSID: NIHMS563426.
        View in: PubMed
      21. Wang H, Liao Z, Zhuang Y, Xu T, Nguyen QN, Levy LB, O'Reilly M, Gold K, Gomez DR. Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database. Int J Radiat Oncol Biol Phys. 2013 Dec 1; 87(5):1071-7. PMID: 24161424; NIHMSID: NIHMS620538 [Available on 12/01/14].
        View in: PubMed
      22. Gold K, Neskey M, William WN. The role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin North Am. 2013 Aug; 46(4):645-56. PMID: 23910475; NIHMSID: NIHMS471531.
        View in: PubMed
      23. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold K, Papadimitrakopoulou V, Swisher SG, Erasmus JJ. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8. PMID: 23287849; NIHMSID: NIHMS419457.
        View in: PubMed
      24. Gold K, Kim ES, Wistuba II, Hong WK. Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem. 2013; 329:221-40. PMID: 22752582; NIHMSID: NIHMS405531.
        View in: PubMed
      25. Wang JL, Gold K, Lippman SM. Natural-agent mechanisms and early-phase clinical development. Top Curr Chem. 2013; 329:241-52. PMID: 22851156.
        View in: PubMed
      26. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold K, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila). 2013 Jan; 6(1):8-17. PMID: 23087048; NIHMSID: NIHMS502168.
        View in: PubMed
      27. Zhang J, Gold K, Kim E. Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs. 2012 Sep; 21(9):1417-26. PMID: 22725255.
        View in: PubMed
      28. Gold K, Wistuba II, Kim ES. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res. 2012 Jun 1; 18(11):3002-7. PMID: 22461458; NIHMSID: NIHMS405533.
        View in: PubMed
      29. Gold K, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila). 2011 Jul; 4(7):962-72. PMID: 21733820; NIHMSID: NIHMS298549.
        View in: PubMed
      30. Lee J, Ryu SH, Kang SM, Chung WC, Gold K, Kim ES, Hittelman WN, Ki Hong W, Koo JS. Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model. Cancer Prev Res (Phila). 2011 Aug; 4(8):1306-15. PMID: 21505178; NIHMSID: NIHMS289438.
        View in: PubMed
      31. William WN, Gold K, Kim ES. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol. 2009 Sep; 20(9):1455-7. PMID: 19704160.
        View in: PubMed
      32. Gold K, Kim ES. Role of molecular markers and gene profiling in head and neck cancers. Curr Opin Oncol. 2009 May; 21(3):206-11. PMID: 19346943.
        View in: PubMed
      33. Gold K, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 2009 Mar 1; 115(5):922-35. PMID: 19156911.
        View in: PubMed
      34. Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer. 2000 Aug 1; 89(3):561-73. PMID: 10931455.
        View in: PubMed
      35. Mandelblatt J, Freeman H, Winczewski D, Cagney K, Williams S, Trowers R, Tang J, Gold K, Lin TH, Kerner J. The costs and effects of cervical and breast cancer screening in a public hospital emergency room. The Cancer Control Center of Harlem. Am J Public Health. 1997 Jul; 87(7):1182-9. PMID: 9240110; PMCID: PMC1380894.
      36. Lerman C, Gold K, Audrain J, Lin TH, Boyd NR, Orleans CT, Wilfond B, Louben G, Caporaso N. Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. Health Psychol. 1997 Jan; 16(1):87-99. PMID: 9028818.
        View in: PubMed